centyl með kaliumklorid filmuhúðuð tafla 2,5 mg+573 mg
karo pharma ab* - bendroflumethiazidum inn; kalii chloridum - filmuhúðuð tafla - 2,5 mg+573 mg
centyl mite með kaliumklorid filmuhúðuð tafla 1,25 mg/573 mg
karo pharma ab* - kalii chloridum; bendroflumethiazidum inn - filmuhúðuð tafla - 1,25 mg/573 mg
darazíð tafla 20 mg/12,5 mg
actavis group ptc ehf. - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg/12,5 mg
mekinist
novartis europharm limited - trametinib - melanoma - Æxlishemjandi lyf - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ekki lítinn klefa lungnakrabbamein (nsclc)trametinib ásamt dabrafenib er ætlað fyrir meðferð fullorðinn sjúklinga með langt ekki lítið klefi lungnakrabbamein með meÐferÐ v600 stökkbreytingu.
koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Æxlishemjandi lyf - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
metadon abcur (metadon novum abcur) tafla 40 mg
abcur ab* - methadonum hýdróklóríð - tafla - 40 mg
dexametason abcur tafla 1 mg
abcur ab - dexamethasonum fosfat - tafla - 1 mg
dexametason abcur tafla 4 mg
abcur ab - dexamethasonum fosfat - tafla - 4 mg
metadon abcur (metadon novum abcur) tafla 10 mg
abcur ab* - methadonum hýdróklóríð - tafla - 10 mg
metadon abcur (metadon novum abcur) tafla 20 mg
abcur ab* - methadonum hýdróklóríð - tafla - 20 mg